Normal view MARC view ISBD view

106P Experience of 22 patients with ROS mutated lung adenocarcinoma treated with crizotinib at a tertiary care center in India

In Annals of oncology
By: Talreja V.
Contributor(s): Pande N.
Material type: materialTypeLabelArticlePublisher: 2018Description: .Subject(s): Mutation India | Lung adenocarcinoma | Tertiary care hospital | Crizotinib In: Annals of oncology Vol. 29, no. suppl_6, mdy314.044Summary: Background: ROS1 hence became recognized as a distinct molecular target in NSCLC.Like ALK rearrangements ROS1 fusions are also found more in never smokers but define a distinct molecular subgroup with both rarely occurring together in same patient Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the treatment of patients with advanced ROS1-positive NSCLC .We report our experience in a tertiary cancer care centre in ROS-1 positive patients. Methods: The present study was a retrospective analysis of a prospectively maintained lung cancer registry in whom the ROS1 mutation status was determined.Genetic Assessments for ROS1 and ALK rearrangements were identified by using FISH.All statistical analyses were carried out using the SPSS software version 22.0. Results: Between January 2015 and December 2017 there were 22 patients who were positive for ROS gene rearrangement. A total of 16 patients took Crizotinib either in first or second line.There were 13 male(60%) and 9 females(40%) in the cohort whose median age was 54 years.The median follow up in Crizotinib received arm was 322 days and 244 days in non-Crizotinib arm.Among the 16 patients who received Crizotinib, 2(12.5%) achieved (CR) as their best response and continue to remain in CR at follow up.13(81.2%) had (PR) as best response and of which on follow up 5 have progressed while 8 continue to maintain response.The median follow-up was 244 days.The estimated medianPFS for the entire cohort of patients was 4 months(95%CI:2.5–5.5 months).The estimated median PFS for the ROS mutant patients was significantly longer at 573 Days(95%CI:318-544 days) as compared to the estimated median PFS for ROS negative patients which was 79 days(95%CI:43-201 days),p=0.00.The estimated median OS for all patients was 13 months(95% CI:10.7–15.3months).The estimated median OS for ROS positive patients was not achieved (95%CI:2.4–25.6 months), while that for ROS negative patients was 79 days (95%CI:7.4–12.6months),p = 0.001. Conclusions: ROS1 rearrangement with incidence of 4% of lung adenocarcinoma represents a important targetable driver mutation in Indian population. Crizotinib is effective treatment option with acceptable side effects in our population.
TMC TMH
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
Available AR19255

Abstract published in the Book of Molecular Analysis for Personalised Therapy (MAP) 2018 14–15 September, Paris, France

Background: ROS1 hence became recognized as a distinct molecular target in NSCLC.Like ALK rearrangements ROS1 fusions are also found more in never smokers but define a distinct molecular subgroup with both rarely occurring together in same patient Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the treatment of patients with advanced ROS1-positive NSCLC .We report our experience in a tertiary cancer care centre in ROS-1 positive patients.

Methods: The present study was a retrospective analysis of a prospectively maintained lung cancer registry in whom the ROS1 mutation status was determined.Genetic Assessments for ROS1 and ALK rearrangements were identified by using FISH.All statistical analyses were carried out using the SPSS software version 22.0.

Results: Between January 2015 and December 2017 there were 22 patients who were positive for ROS gene rearrangement. A total of 16 patients took Crizotinib either in first or second line.There were 13 male(60%) and 9 females(40%) in the cohort whose median age was 54 years.The median follow up in Crizotinib received arm was 322 days and 244 days in non-Crizotinib arm.Among the 16 patients who received Crizotinib, 2(12.5%) achieved (CR) as their best response and continue to remain in CR at follow up.13(81.2%) had (PR) as best response and of which on follow up 5 have progressed while 8 continue to maintain response.The median follow-up was 244 days.The estimated medianPFS for the entire cohort of patients was 4 months(95%CI:2.5–5.5 months).The estimated median PFS for the ROS mutant patients was significantly longer at 573 Days(95%CI:318-544 days) as compared to the estimated median PFS for ROS negative patients which was 79 days(95%CI:43-201 days),p=0.00.The estimated median OS for all patients was 13 months(95% CI:10.7–15.3months).The estimated median OS for ROS positive patients was not achieved (95%CI:2.4–25.6 months), while that for ROS negative patients was 79 days (95%CI:7.4–12.6months),p = 0.001.

Conclusions: ROS1 rearrangement with incidence of 4% of lung adenocarcinoma represents a important targetable driver mutation in Indian population. Crizotinib is effective treatment option with acceptable side effects in our population.

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha